

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 July 2005 (28.07.2005)

PCT

(10) International Publication Number
WO 2005/067896 A1

- (51) International Patent Classification⁷: **A61K 9/70**, C08L 39/00
- (21) International Application Number: PCT/US2004/029256
- (22) International Filing Date: 8 September 2004 (08.09.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 10/739,514 18 December 2003 (18.12.2003) US
- (71) Applicant (for all designated States except US): **KIMBERLY-CLARK WORLDWIDE, INC.** [US/US]; 401 N. Lake Street, Neenah, Wisconsin 54956 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **YAHIAOUI, Ali** [US/US]; 5040 Foxberry Lane, Roswell, Georgia 30075 (US). **KELLER, Caron** [US/US]; 6872 So. Old Highway 91, MaCammon, Idaho 83250 (US). **BORDERS, Richard, Arnold** [US/US]; 3749 Townsend Way, Marietta, Georgia 30062 (US).
- (74) Agents: **LETSON, William, W.** et al.; **KIMBERLY-CLARK WORLDWIDE, INC.**, 401 N. Lake Street, Neenah, Wisconsin 54956 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: ELECTRICALLY CONDUCTIVE ADHESIVE HYDROGELS WITH A THERMALLY ACTIVATED CHEMICAL INITIATOR

(57) Abstract: A composition providing electrically conductive adhesive hydrogels suitable for use as skin contact adhesives and, particularly, suitable for use as an electrical interface for disposable medical devices. The present hydrogels provide for reduced skin irritation and/or malodor properties, hydrate a subject's skin, readily wet around a subject's skin surface hair, and protect against burning of a subject upon or due to electrical stimulation through the hydrogel. These hydrogels generally include a monomer, a thermally activated chemical initiator, and a cross-linking agent. The present hydrogels also desirably include a solubilizer. The present hydrogels also desirably may include a buffer system to help prevent discoloration of the hydrogels and/or hydrolysis of the hydrogels as well as to improve shelf-life. Other additives such as conductivity enhancers, pharmaceuticals, humectants, plasticizers, skin health agents, etc. may be added to the present hydrogels either before or after curing.



WO 2005/067896 A1

**ELECTRICALLY CONDUCTIVE ADHESIVE HYDROGELS WITH A THERMALLY
ACTIVATED CHEMICAL INITIATOR**

BACKGROUND

5 At present, electrically conductive adhesive solid hydrogels and liquid gels are used in the medical device field to provide an electrical interface to the skin of a subject to couple electrical signals into and/or out of the subject (e.g., for diagnostic and/or monitoring uses) and/or to couple electrical stimulus into the subject (e.g., for treatment and/or preventative uses). However, the present hydrogels and liquid gels are inadequate
10 in various aspects.

 Prior hydrogels exhibit problems with their adhesive and/or cohesive strength in that they do not sufficiently adhere to the skin, they are insufficiently cohesive to allow for easy removal, and/or they are adherent to themselves such that they must be physically separated, as by a barrier film, to ensure separability (no straight face-to-face, gel-to-gel,
15 configurations). See, e.g., Gilman, et al., U.S. Pat. No. 5,402,884 (a package system providing electrical communication between two hydrogel portions, but still requiring separation of the two hydrogel portions). Additional problems with prior hydrogels concern sufficiently hydrating the skin in contact with the hydrogel and, therefore, problems with sufficiently lowering the skin's electrical resistance thereby frequently resulting in heating
20 to a point of burning the skin upon electrical stimulation. See, e.g., E. McAdams, "Surface Biomedical Electrode Technology," Int'l Med. Device & Diagnostic Indus. pp. 44-48 (September/October 1990).

 Further problems with prior hydrogels include insufficiently wetting around skin hair and resultant problems with insufficiently contacting the skin. This leads to insufficient
25 electrical contact thereby frequently resulting in decreased efficacy of defibrillation and increased incidences of heating to the point of burning the skin upon electrical stimulation and/or problems of requiring preparation of skin surfaces prior to use thereby resulting in slowing the speed of procedures. Further still, electrical pulses transmitted through prior hydrogels to a patient cause hydrolysis of the gel, and this problem is exacerbated with
30 medical stimulation equipment used for defibrillation and/or cardiac pacing because these types of stimulation equipment usually deliver higher voltages and currents to the patient which increases the rate of hydrolysis. For example, defibrillation equipment typically delivers up to 5,000 volts to the patient at a maximum current of 60 amps, and cardiac pacing equipment commonly delivers up to 300 volts to the patient at a maximum current
35 of 0.2 amps.

Yet another problem with prior hydrogels is that the hydrogels often have an unpleasant odor associated with them. Some prior hydrogels also exhibit properties that are irritating to the skin of a patient. Skin irritation issues often arise where polymerization of the functional monomer and/or other monomeric residues in the hydrogel is not complete. In some cases, other undesired monomeric residues are present and, over time after manufacture, may come in direct contact with the patient skin and thus may further cause skin irritation.

Liquid gels experience similar problems and have the additional problem of not retaining a set shape over time due to their fluidity which affects their ease of use and storability, and problems of requiring even more time for clean-up due to their lack of cohesive strength.

Therefore, a new hydrogel which is suitable for use in skin-contact and medical devices, and which addresses and resolves these problems is needed.

SUMMARY OF THE INVENTION

In response to the difficulties and problems discussed above a composition for an electrically conductive hydrogel has been developed. The composition includes a monomer, a first initiator, and a cross-linking agent, wherein the first initiator is a thermally activated chemical initiator.

Alternatively, a composition for an electrically conductive hydrogel may include a monomer, a thermally activated chemical initiator, a cross-linking agent, and a solubilizer, wherein the monomer is about 10 to about 80% by weight of the composition and wherein the composition is characterized in that the solubilizer allows for a higher initiator concentration to be solubilized in the composition; and wherein the composition has a higher polymerizing potential than a similar composition without the solubilizer. The composition may include one or more second initiators, wherein the one or more second initiators are capable of activating the thermally chemical initiator.

The compositions of the present invention may be incorporated in a number of products. One example is an electrode comprising an electrically conductive adhesive hydrogel formed from a composition having a monomer, a first initiator, a cross-linking agent, wherein the first initiator is a thermally activated chemical initiator.

The invention will be more fully understood and further features and advantages will become apparent when reference is made to the following detailed description of exemplary aspects of the invention and the accompanying drawings.

DETAILED DESCRIPTION OF THE PRESENT INVENTION

The present invention relates to electrically conductive adhesive hydrogels and, more particularly, to electrically conductive adhesive hydrogels suitable for use as a skin-contacting electrical interface for medical devices.

5 Hydrogel precursors of the present invention may be used to form electrically conductive adhesive hydrogels which are suitable for use as skin-contact adhesives and are good electrical conductors suitable for use in disposable medical devices, for example. Desirable skin-contact adhesives are non-irritating, are sufficiently wet to substantially wet and adhere to skin, and are sufficiently cohesive to be readily removable. Such adhesives
10 further would sufficiently contact and wet skin to allow passage of electrical current without substantially adversely affecting the hydrogel or skin.

A number of different hydrogel precursor formulations are commercially available, at least one of which includes a photo initiator to promote the polymerization of the monomers in the precursor. Many of the prior formulations exhibit undesirable properties
15 including issues with skin irritation, odor, electrical conductivity, adhesiveness, and the like. It has been discovered that some of those problems are, in large part, the result of poor polymerization of the monomers in the hydrogel precursors. That is, the functional monomers and other monomeric residues in the hydrogel precursors are not fully polymerizing thereby leaving residual monomer and/or by-products, which can cause or
20 result in the some of the above undesirable properties.

Conventional industrial polymerization processes seldom yield complete reactions and thus residual monomer remains. Therefore, whether or not an initiator was present in prior hydrogel precursors, polymerization of the monomers in the prior hydrogels frequently was not complete and residual functional monomer and other monomeric
25 residues remained. As the presence of the residual functional monomer and/or other monomeric residues is believed to be a cause of malodor and/or may result in skin irritation, the presence of residual functional monomer and other monomeric residues is desirably avoided or minimized. For instance, it has been discovered that the presence of an acrylic type residual monomer, such as acrylic acid or methyl acrylate, in a hydrogel
30 may lead to an odor issue and/or skin irritation.

The present hydrogels have unique and improved properties as compared to other conductive hydrogels. More particularly, the present polymerizing formulations or hydrogel precursors exhibit enhanced polymerization, thereby reducing the amount of residual functional monomer and/or other monomeric residues in the hydrogel which are
35 unpolymerized and are thus available to cause or result in malodor of the resulting hydrogel and/or skin irritation of a subject.

It will be appreciated that while reference is generally made throughout this disclosure to a hydrogel, in addition to referring to the end product, the term hydrogel, also may refer to the polymerizing formulation or hydrogel precursor which is converted to a hydrogel upon exposure to certain conditions (e.g., UV curing, heat, etc.) as discussed elsewhere herein.

By the term "similar composition" what is meant is a composition which uses essentially the same manufacturing processes and materials as the inventive composition but in which the inventive item is lacking. According to Webster's New Collegiate Dictionary (1980), "similar" means 1) having characteristics in common; strictly comparable, 2) alike in substance or essentials; corresponding. Using this commonly accepted meaning of the word similar, this term means that all other conditions are essentially the same, within manufacturing tolerances, except for the inventive conditions mentioned.

At least one prior hydrogel composition (e.g., U.S. Patent No. 5,800,685, the disclosure of which is incorporated herein in its entirety) is known to have included a monomer, a cross-linking agent, and a photo initiator. However, the types of initiator cited in the '685 patent have limited water solubility in the precursor described. Therefore, if a higher amount of initiator (i.e. above the solubility limit) is needed to achieve a more complete polymerization that is not possible with the teachings of the '685 patent. Thus, the '685 patent presents a situation where there may not have been enough initiator present in soluble form to fully polymerize the monomer. Alternatively, if a higher concentration of hydrophobic initiator was present, the hydrogel became cloudy due to phase separation as a result of solubility limits being reached and exceeded by the addition of the initiator.

It has been discovered that the addition of a solubilizer to a hydrogel precursor allows for enhanced polymerization of the monomer, thereby leading to a reduction in or the avoidance of the presence of residual functional monomer and/or other monomeric residue. Such a reduction can provide for the provision of certain properties or the reduction or elimination of other properties depending on the beginning monomers and initiators of the hydrogel. Specifically, where the polymerization process is enhanced by the inclusion of a solubilizer so as to allow a higher level of initiator to be included in the hydrogel precursor without the difficulties discussed above, the amount of residual functional monomer and/or other monomeric residue may be reduced or avoided, thereby reducing the odor of the resulting hydrogel as well as reducing the risk of skin irritation of a user.

The present hydrogels become more stable with an associated extension of their shelf life which is another advantage of the present hydrogels not observed in previous hydrogels. That is, the more complete the polymerization process the more stable the hydrogel is during storage. This stability and extended shelf life can provide for significant cost savings as fewer products will fail post-manufacturing. Additionally, the stability and extended shelf life are expected to contribute to a decrease in the chances of getting a failed or defective product in an emergency situation provided a non-expired product is selected.

It will be appreciated that certain of the suitable solubilizers (e.g., cyclodextrin, cyclodextrin derivatives, and the like) also may act as a complexing and stabilizing agent. Thus, even in those aspects of the present invention wherein the concentration of initiator in the hydrogel precursor is below the solubility limit, without the addition of a solubilizer, and the addition of solubilizer would heretofore have been considered unnecessary and non-beneficial, the addition of a solubilizer which is or acts as a complexing agent can reduce the volatility of certain molecules (typically those associated with malodor) in the hydrogel and thus reduce the odor of the hydrogel.

Additionally, suitable solubilizers may act as carriers for desired hydrophobic ingredients (e.g., lipids, vitamins, anti-oxidants, drugs, fragrance, and other skin care ingredients, etc.) to help solubilize them in water so as to allow them to become more homogeneously integrated within the hydrogel.

The use of a solubilizer as a complexing agent and/or a carrier as noted above may exist whether the initiator present in the hydrogel precursor is hydrophilic or hydrophobic. However, where a hydrophilic initiator is used, the complexing agent can act as a carrier for a hydrophobic agent such as a skin care ingredient (e.g., lipid, etc.). It will be further appreciated that a solubilizer can act as a complexing agent and/or a carrier regardless of the initiator concentration compared to its solubility limit in the hydrogel precursor.

As indicated above, while prior hydrogel precursors may have included a hydrophobic initiator, the inclusion of excess hydrophobic initiator (an amount above the solubility limit therefor in the hydrogel precursor) is generally not considered beneficial and, in fact, can be detrimental as it can cause cloudiness of the hydrogel or result in phase separation.

The present invention presents a solution to some of the problems associated with prior hydrogels as at least one aspect of the present invention provides for the inclusion of initiator in an amount above its unmodified solubility limit (the solubility limit of the initiator in a hydrogel precursor without the addition of a solubilizer), thereby allowing for enhanced

polymerization of the functional monomer and other monomeric residue of the hydrogel precursor as compared to a similar composition without the solubilizer.

For example, where an initiator such as IRGACURE[®] 184 (available from Ciba Specialty Chemicals, Inc., Tarrytown, NY) is present without a solubilizer, the solubility
5 limit of the initiator in a particular hydrogel precursor may be about 0.15% by weight of the hydrogel precursor. The addition of IRGACURE[®] 184 in an amount above its solubility limit will result in super saturation causing or resulting in cloudiness and/or phase separation; however, polymerization will not be enhanced. The inclusion of a solubilizer such as cyclodextrin or a cyclodextrin derivative can raise the solubility level of the
10 hydrophobic initiator in the hydrogel precursor and enhances the prospect of a more complete polymerization and formation of a more homogenous hydrogel.

The inclusion of a solubilizer and the ability to include a higher level of solubilized initiator can be significant in certain aspects of the present invention in view of the fact that the functional monomers received from suppliers generally contain a polymerization
15 inhibitor such as monomethyl ether hydroquinone (MEHQ) which is added to the monomer by the manufacturer in order to prevent spontaneous polymerization of the monomer during shipping and/or storage. While the inhibitor makes the monomer more stable, the inhibitor also becomes problematic during the hydrogel manufacturing process. That is, the inhibitor hinders the polymerization process because it quenches radicals in the same
20 manner as it inhibits spontaneous polymerization of the functional monomer during storage. In addition, oxygen dissolved during preparation of the monomer solution also can have an inhibitory effect on the overall polymerization process. Thus, the presence of an inhibitor (e.g., MEHQ) and oxygen in solution counteracts the initiator. Thereby, the initiator is desirably present in soluble form in an amount to overcome the inhibiting effect
25 of all inhibitors, such as MEHQ, dissolved oxygen and other radical scavenging moieties, so that the polymerization reaction desirably may go to or near completion.

As will be appreciated where an amount of initiator which is in solution (rather than separated out because of over saturation) and thereby is capable of initiating polymerization is consumed or neutralized by an inhibitor less soluble initiator is available
30 for polymerization of the monomer. Thus, it can be desirable to raise the amount of initiator which is in solution and therefore available for polymerization of the monomer.

Further, the inclusion of an initiator in an amount which exceeds its solubility limit in the aqueous environment of the hydrogel precursor is different than the inclusion of or the ability to include an initiator in an amount above its normal or unmodified solubility limit in
35 the aqueous environment, but which is also at or below the modified or elevated solubility limit created by the addition of a solubilizer. That is, the inclusion of the solubilizer

increases the amount of initiator which may be solubilized and thus is available to enhance the initiation process and counteract the radical quenching of the inhibitors, leaving a higher quantity of solubilized initiator available for polymerization of the functional monomer and/or other monomeric residues than would be present or available for polymerization in the absence of the solubilizer. Enhanced polymerization of the functional monomer and other monomeric residues (e.g., acrylic acid, methyl acrylate, etc.) in the hydrogel precursor can result in a reduction of the odor of the resulting hydrogel and the potential for irritation of the skin as compared to the hydrogel which would have been formed without the presence of the solubilizer.

As noted above, the solubilizer can enable enhancement of the polymerization of the functional monomer and other monomeric residues. In some aspects, the solubilizer provides for a higher soluble initiator concentration without experiencing the difficulties noted above. In others the solubilizer can act as a complexing agent to reduce odor of the hydrogel, and/or the solubilizer can act as a carrier for a hydrophobic ingredient (e.g., lipids, vitamins, anti-oxidants, drugs, fragrance, other skin care ingredients, and the like) to help homogeneously solubilize them in the hydrogel so their attributes may be taken advantage of.

Note that where the sole function of the addition or inclusion of a solubilizer in the present invention is to achieve or allow for the achievement of higher initiator solubility levels and the results thereof, the initiator is limited to hydrophobic initiators, as hydrophilic initiators generally will not present the same issues in the amounts of initiator contemplated by the present invention. The limitation to the use of a hydrophobic initiator applies where only one initiator is present. Where more than one initiator is present in the hydrogel and the sole function of the addition or inclusion of a solubilizer is to achieve or allow for the achievement of higher initiator solubility levels and the results thereof, then at least one of the initiators should be an initiator that has a solubility limit issue in the particular precursor. However, either hydrophilic or hydrophobic initiators can be used where a solubilizer is included for another purpose (e.g., as a complexing agent or carrier for other hydrophobic ingredients) or in addition to modifying or elevating solubility limit of an initiator in the hydrogel precursor.

With regard to the functional monomer, it is contemplated that the hydrogels may be formed from any suitable monomer. In at least one aspect of the present invention, the hydrogel may be formed by free radical polymerization in the presence of water. A multifunctional cross-linking agent is also included. Initiation of the formation of the hydrogel may be begun by exposure to sufficient heat to trigger a thermally activated chemical initiator (TACI). While only one TACI initiator is necessary, the hydrogel

precursors may contain one or more second initiators. The second initiators can be photo-initiators or chemical initiators such as those activated by heat or by reduction/oxidation (redox) reactions. In at least one aspect of the present invention, at least one of the second initiators will be a photo initiator capable of exothermically reacting with the functional monomer and/or other monomeric residues to produce enough heat to trigger at least a portion of the TACI. When a photo initiator is present, initiation of the formation of the hydrogel may be begun by ultra-violet curing the monomer with the photo initiator and the cross-linking agent. As noted above and as discussed in more detail herein, the heat generated by the photo initiator reacting with the monomer can be used to trigger the TACI.

While any suitable monomer is contemplated by the present invention, exemplary functional monomers include: N-vinyl pyrrolidone (NVP), hydroxyethyl methacrylate (HEMA), methacrylic acid (MA) or its salt, styrene sulfonic acid (SSA) or its salt, potassium sulfopropyl acrylate (KPSA), dimethyl acrylamide (DMA), dimethyl amino ethyl methacrylate (DMAEMA) or its quaternary salt derivative, acrylamido methyl propane sulfonic acid (AMPS) or its salt, and the combination of any of the above. Desirably, the hydrogels of the present invention are made from various classes of monomers including acrylates, vinyls, amides, esters, etc, of which can be electrically neutral, cationic or anionic. Combination of functional monomers also is possible to achieve desired physical, chemical mechanical and electrical properties. Compared to prior hydrogels, acrylate hydrogels (for example) of the present invention hydrate more efficiently and more sufficiently a subject's skin surface to which they are applied and, therefore, more efficiently and more sufficiently lower the skin surface's electrical resistance resulting in lower generation of heat and lower incidence of burning upon electrical stimulation. In addition, the present hydrogels more effectively wet around skin hair and, consequently, more sufficiently contact a subject's skin resulting in increased efficacy in procedures such as defibrillation as well as reduced heating and burning of skin surfaces and, generally require no preparation of the skin surface prior to use. Furthermore, the present hydrogels are self-preserving and are resistant to degradation upon exposure to radiation for sterilization purposes.

Generally, one aspect of the present hydrogel precursor includes between about 10 to about 80% by weight of the monomer, more desirably between about 40 to about 75% by weight of the monomer, and even more desirably between about 50 to about 75% by weight of the monomer.

Examples of specific cationic acrylates which the inventors have found commercially available are: acryloyloxyethyltrimethyl ammonium chloride which is readily available from CPS Chemical Co. (New Jersey) or Allied Colloid (U.K.);

acryloyloxyethyltrimethyl ammonium methyl sulfate which is also available from CPS Chemical Co. or Allied Colloid; and, acrylamidopropyltrimethyl ammonium chloride, which is available from Stockhausen (Germany). The desired process for making hydrogels with these exemplary acrylates is described in detail below.

5 A cationic acrylate hydrogel suitable for the present invention will generally be somewhat clear in color, viscous, and tacky to the touch. The hydrogel tends to be sufficiently adhesive to a subject's skin, yet sufficiently cohesive to be easily removable from the subject's skin and separable from itself. As noted above, the hydrogels suitable for the present invention can be formed by in-situ free radical polymerization of a water
10 soluble monomer in the presence of water. Depending on the makeup of the precursor this may be done by subjecting the monomer with a TACI and a multi-functional cross-linking agent to heat (e.g., conventional heating oven, hot plate, etc.). For example, an appropriate acrylate monomer, water, optional additional conductor(s) (e.g., sodium chloride, potassium chloride, or other salts), a TACI (e.g., sodium metabisulfite), and multi-
15 functional cross-linker (e.g., methylene-bis-acrylamide, etc.) may be combined, placed in a mold, and exposed to heat to trigger the TACI. An optional solubilizer (e.g., cyclodextrin, etc.) could also be included. The TACI may be triggered by any number of suitable heat or thermal sources.

Although TACIs have traditionally been triggered by a conventional heating oven,
20 hot plate, or other comparable heat sources, the present invention also contemplates the triggering of the TACI by the heat generated from a photo initiator's reaction with a monomer following exposure to a UV source. That is, where a photo initiator is also present in a precursor composition, the composition may be subjected to UV energy, desirably by way of ultra-violet curing, to begin polymerization of the composition and to
25 trigger the TACI to further contribute to polymerization. For example, an appropriate acrylate monomer, water, optional additional conductor(s) (e.g., sodium chloride, potassium chloride, or other salts), a TACI (e.g., sodium metabisulfite), a second initiator or catalyst (e.g., IRGACURE[®] 184, etc.), and multi-functional cross-linker (e.g., methylene-bis-acrylamide, etc.) may be combined, placed in a mold, and exposed to an appropriate
30 amount of ultra-violet radiation. Again, an optional solubilizer (e.g., cyclodextrin, etc.) could also be included. It will be appreciated that while a UV source also may contribute heat which may assist with the triggering of a TACI, in most instances unless prolonged exposure is allowed, the heat transferred from the UV source to the composition will need to be supplemented in order to trigger the TACI.

35 Examples of co-monomers which may be used with the present invention include co-monomers soluble in water and, even more desirably, include anionic co-monomers.

The amount of co-monomer to be used may be in the range of about 5 to about 50% by weight, desirably about 10 to about 30% by weight, based on the amount of reactants used. Examples of suitable co-monomers include: unsaturated organic carboxylic acids such as acrylic acid, methacrylic acid, maleic acid, itaconic acid, and citraconic acid and salts thereof, unsaturated organic sulfonic acids such as styrene sulfonic acid, methallyl sulfonic acid, 2-sulfoethyl acrylate, 2-sulfoethyl methacrylate, 3-sulfopropyl acrylate, 3-sulfopropyl methacrylate, acrylamido-methylpropane sulfonic acid and salts thereof, N,N-dimethylacrylamide, vinyl acetate, other radically polymerizable ionic monomers containing a carbon-carbon double bond, and non-N-vinyl lactam co-monomers useful with N-vinyl lactam monomeric units such as N-vinyl-2-pyrrolidone, N-vinyl-2-valerolactam, N-vinyl-2-caprolactam, and mixtures thereof. Among the ionic monomers enumerated above, particularly desirable selections are 3-sulfopropylacrylate or methacrylate, and salts thereof. Examples of cations involved in the formation of such salts include sodium, potassium, lithium, and ammonium ions. Ionic monomers may be used singly or in a mixture of two or more monomers.

Any suitable solubilizer or combination of solubilizers is contemplated. The desirability of a specific solubilizer and/or the amount thereof which is included in hydrogel precursor may vary or depend in part on the other components and quantities thereof selected to make up the hydrogel precursor. Exemplary solubilizers include but are not limited to cyclodextrin, cyclodextrin derivatives, and hydrotropes. Specific exemplary cyclodextrin derivative solubilizers that are known to work in at least one aspect of the present invention include hydroxypropyl beta-cyclodextrin (HP- β -CD) (available from Cargill Dow, Minnetonka, MN), gamma cyclodextrin (γ -CD) (available from Wacker Biochem Corporation, Adrian, MI) and other polymerizable cyclodextrin derivatives such as methacryloyl cyclodextrin.

If a specific initiator is selected, then some solubilizers may be more desirable than others. That being said, it is contemplated that a solubilizer may be present in an amount up to about 20% by weight of the hydrogel precursor and, more desirably, between about 0.5% to about 5% by weight of the hydrogel precursor.

Present hydrogels may include a buffer system to help control the pH, prevent discoloration, and/or prevent breakdown due to an extended presence of water (i.e., hydrolysis). The use of a buffer system with the present hydrogel is desired to provide the hydrogel with a commercially suitable shelf-life (i.e., a shelf-life of over one year) without discoloration. Suitable buffers include but are not limited to sodium potassium tartarate, and/or sodium phosphate monobasic, both of which are commercially readily available from Aldrich Chemical Co., Inc., Milwaukee, WI.

In addition, the use of buffers also helps to prevent electro-chemical burning of a subject by helping to prevent pH changes and/or shifts as a current is driven through a pair of hydrogel electrodes. Typically, in prior systems, as current is driven through a pair of hydrogel electrodes, one electrode becomes more acidic (i.e., its pH decreases) while
5 the other electrode becomes more basic (i.e., its pH increases). This pH shifting problem is particularly prevalent if current is driven through such electrodes for a long period of time (e.g., over 1 hour), such as during a procedure wherein a patient's heart is being paced. The desired use of a buffer system as is suggested in the present invention helps safeguard against such pH changes as current is driven therethrough and thereby enables
10 use of the electrodes made from the present hydrogel for longer periods (e.g., over 24 hours) without electro-chemical burning.

Therefore, it is desired that buffer be included to stabilize the resulting polymer, to avoid hydrolysis of the hydrogel, and to avoid pH shifts due to the passage of direct current through the hydrogel. Buffers help both to reduce or prevent corrosion of metal
15 conductors and also are conductivity enhancers themselves. Some buffers prevent undesirable yellowing of the hydrogel. The present hydrogel may include sufficient buffer to maintain the pH of the hydrogel in a range of about 3 to about 8, and more desirably about 4 to about 6, but the pH may be adjusted as desired. In most aspects of the present invention, a buffer may be present in the hydrogel precursor in an amount up to about
20 10% by weight, and more desirably from about 0 to about 5% by weight of the hydrogel precursor.

Although a buffer also may be a conductivity enhancer, the quantities of the buffer and conductivity enhancers described herein are independent of one another. That is, if a particular hydrogel precursor is intended to include 1% by weight of a conductivity
25 enhancer and 1% by weight of a buffer, the buffer which also may happen to be a conductivity enhancer can but generally will not count towards the amount of enhancer included.

The present invention also contemplates the inclusion of other additives, such as conductivity enhancers, pharmaceuticals, humectants, plasticizers, skin health agents,
30 and the like. These other additives may be included either before or after a curing step. The appropriateness of such additives is generally dependent upon the intended end use of the particular hydrogel.

Any suitable additive or combination of additives such as those suggested above is contemplated. The specific additive and/or the amount thereof which is included may vary
35 or depend in part on the other components and quantities thereof selected to make up the hydrogel. Exemplary skin health agents and/or skin care ingredients include but are not

limited to vitamins (e.g., B, D, E, E acetate, etc.), antioxidants, chitosan, aloe Vera, hyaluronic acid (HA), heparin, chondroitin sulfate, dextran sulfate, and collagen IV. Still other exemplary additives may include but are not limited to anti-inflammation agents, anti-oxidants, aesthetic agents (e.g., color dyes to alter appearance of the hydrogels), or fragrances.

As noted above, any suitable conductivity enhancer is contemplated. The specific enhancer and/or the amount thereof which is included in the hydrogel may vary or depend in part on the other components, and quantities thereof selected to make up the hydrogel. Exemplary conductivity enhancers include but are not limited to salts such as potassium chloride, sodium chloride, potassium sulfate, and the like. These salts are desired inasmuch as human bodies use them for conduction. Additional examples of salts which may be appropriate are lithium chloride, lithium perchlorate, ammonium chloride, calcium chloride, and/or magnesium chloride. Other chloride salts, iodide salts, bromide salts, and/or halide salts also may be suitable.

Other salts, such as salts of weak organic acids or polymeric electrolytes may be desirable. These salts are compatible with human bodies and with the chemistry of the hydrogels of the present invention and may be used as conductivity enhancers where desired chloride salts might interfere (i.e., corrode) with aluminum and/or stainless steel metal components used to interface the hydrogel with medical equipment. Examples of salts which may be suitable, include sodium citrate or magnesium acetate.

Although use of a conductivity enhancer is optional, the amount of conductivity enhancer in a hydrogel of the present invention is desirably in the range of none to an amount which will enhance the conductivity of the hydrogel, and more desirably a conductivity enhancer will be present in an amount between about 0 to about 15% by weight of the hydrogel precursor and, even more desirably, less than about 5% by weight of the hydrogel precursor.

The addition of conductivity enhancers may be desired even though the hydrogel of the present invention is a polyelectrolyte ionically disassociated in water and, therefore, conductive. In utility, a lower specified quantity of polyelectrolyte (and thus a hydrogel having a correspondingly lower viscosity) may be desired in situations such as when the hydrogel must wet around chest hair. In such cases, the addition of a conductivity enhancer may be useful.

However, while the addition of a conductivity enhancer to a hydrogel or hydrogel precursor has generally been thought to provide for better electrical conductivity when compared to hydrogels without the added conductivity enhancer, it has been discovered that at least some aspects of the present invention which do not include an added

conductivity enhancer demonstrate better in use conductivity as compared to those hydrogels which included a conductivity enhancer. For example, in certain instances, salts, despite being inherently electrically conductive because of their ionicity, may negatively yield undesirable effects such as the "salting out" effect which may result in phase separation and/or contribute to the reduced conductivity of certain formulations. This is especially true the longer the shelf life a hydrogel may be subjected to.

As indicated herein, a buffer and/or one or more of the optional polyelectrolyte additives (e.g., HA, chondroitin sulfate, phospholipids, etc.) may exhibit conductivity enhancing properties; however, the buffer and/or polyelectrolyte additives are not contemplated to be included in the determination of the amount of a conductivity enhancer in the hydrogel as the buffer and/or polyelectrolyte additives may not form a continuous path within the gel and between the gel and the skin.

As is mentioned above, initiators are used in the polymerization of the hydrogel precursors described herein. While the present invention is directed to a hydrogel precursor with a TACI, as discussed herein, other initiators are also contemplated for inclusion. Examples of photo initiators which may be used include IRGACURE[®] 184 (1-hydroxycyclohexyl phenyl ketone), IRGACURE[®] 2959 (4-(2-hydroxyethoxy)phenyl-(2-hydroxy-2-methylpropyl)ketone)), and DAROCURE[®] 1173 (α -hydroxy- α , α -dimethylacetophenone), all commercially available from Ciba Specialty Chemicals. These UV initiators are desired because they are non-yellowing. Other initiators which may maintain the desired water-white and water-clear appearance of the present hydrogels also are desired. Additional examples of suitable initiators (which may be photo initiators or thermal initiators) may include benzoyl peroxide, azo-bis-isobutyro-nitrile, di-t-butyl peroxide, bromyl peroxide, cumyl peroxide, lauroyl peroxide, isopropyl percarbonate, methylethyl ketone peroxide, cyclohexane peroxide, tutyhydroperoxide, di-t-amyl peroxide, dicumyl peroxide, t-butyl perbenzoate, benzoin alkyl ethers (such as benzoin, benzoin isopropyl ether, and benzoin isobutyl ether), benzophenones (such as benzophenone and methyl-o-benzoyl benzoate), acetophenones (such as acetophenone, trichloroacetophenone, 2,2-diethoxyacetophenone, p-t-butyltrichloro-acetophenone, 2,2-dimethoxy-2-phenyl-acetophenone, and p-dimethylaminoacetophenone), thioxanthenes (such as xanthone, thioxanthone, 2-chlorothioxanthone, and 2-isopropylthioxanthone), benzyl 2-ethyl anthraquinone, methylbenzoyl formate, 2-hydroxy-2-methyl-1-phenylpropane-1-one, 2-hydroxy-4'-isopropyl-2-methyl propiophenone, α -hydroxy ketone, tetramethyl thiuram monosulfide, allyl diazonium salt, and combinations of camphorquinone and ethyl 4-(N,N-dimethylamino)benzoate. Other suitable initiators may

be found in, for example, Berner, et al., "Photo Initiators--An Overview", J. Radiation Curing (April 1979), pp. 2-9.

Although only one initiator is necessary, the hydrogel may contain one or more second initiators. The one or more second initiators can be photo or chemical initiators.

5 Where there is only one initiator, the amount of initiator is desirably within the range of about 0.01 to about 5% by weight of the hydrogel precursor, more desirably, within the range of about 0.05 to about 2% by weight of the hydrogel precursor and, even more desirably, within the range of about 0.1 to about 0.5% by weight of the hydrogel precursor. Where one or more second initiators are present, the amount of one or more
10 second initiators is desirably within the range of about 0.01 to about 5% by weight of the hydrogel precursor, and more desirably within the range of about 0.05 to about 2% by weight of the hydrogel precursor and, even more desirably, within the range of about 0.1 to about 0.5% by weight of the hydrogel precursor. However, where multiple initiators are present, it is generally desirable that the combined amount of the initiators be about 5% or
15 less by weight of the hydrogel precursor, and more desirably within the range of about 0.02 to about 5% by weight of the hydrogel precursor. Where one or more second initiators are present it is desirable for at least one of the initiators to be a photo initiator.

UV curing parameters to achieve desired polymer properties are well known to those skilled in the art. A photo initiator for the present purposes tends to operate by
20 absorbing select wavelengths of UV to produce radical initiating species to induce monomer polymerization. The wavelengths and curing area set the style of UV bulb used in the curing process. Inhibition of polymerization due to dissolved oxygen, monomer inhibitors, or other radical scavenging moieties may be overcome by changing the power, by pulsing, and/or by using initiator accelerators.

25 It will be appreciated that each photo initiator is responsive to a specific or narrow wavelength range of UV light. At least one aspect of the present invention takes advantage of this property and incorporates at least one photo initiator in a hydrogel precursor. The addition of more than one photo initiator in a hydrogel precursor allows for a broader range of the energy or range of wavelengths emitted by a UV source to be
30 utilized. The utilization of multiple initiators can further reduce solubility limit concerns and related compatibility concerns, as more efficient polymerization may be able to be achieved with two initiators present in a hydrogel precursor than with either of the initiators used alone at the same overall initiator concentration.

35 While the use of solubilizers is contemplated so as to alleviate solubility concerns, it is also believed that the inclusion of multiple initiators which may be present at levels which independently would have been insufficient to obtain the desired polymerization can

enable the use of additional initiators whose solubility limits in hydrogel precursors effectively precluded their use previously.

The synergistic effect of initiators has not been previously identified or exhibited in previous hydrogels which incorporated one photo initiator, if any initiator at all. It is further
5 believed that the inclusion of initiators having different rates of initiation and/or the inclusion of initiators which begin initiation of polymerization of the monomer at different times relative to each other (such as that which may be experienced by multiple initiators (e.g., a TACl and a photo initiator)) contributes to a higher yielding polymerization. That is, for example, where two photo initiators are included, one may have a lower UV
10 wavelength trigger and may be more energetic (providing for a faster rate of initiation and reaction) than the other initiator which is triggered by a higher UV wavelength or range. The faster initiator may also die or be consumed faster than the other. It is contemplated that it may be advantageous to have polymerization occur at different rates and/or at a mixed rate which may not be obtainable with one initiator or with an initiator which is
15 suitable for a particular hydrogel precursor. An example of initiators which are not triggered or activated simultaneously, may be found in the present invention where a photo initiator and a TACl are in a hydrogel precursor, and the photo initiator is triggered by a UV source and reacts with the monomers in the precursor so as to generate heat to trigger the TACl.

20 While numerous combinations and variations of initiators are possible, it is believed that the combination of multiple initiators provides more favorable kinetics which afford a higher probability of more extensive polymerization of the monomer and/or other monomeric residues.

Of course, if desired or necessary multiple initiators also could be present at
25 elevated solubility levels. In either instance, the inclusion of multiple initiators can result in a more completely polymerized hydrogel.

As suggested above, it is a further discovery of the present invention that a photo initiator also may be included in the hydrogel precursor such that when exposed to UV energy the photo initiator will react with a functional monomer and/or other monomeric
30 residue and generate heat to trigger the TACl. Desirably, the photo initiator will be selected such that when exposed to the UV energy, the heat generated by the resulting reaction is sufficient to trigger the TACl. That is, as radical polymerization reactions induced by photo initiators are known to be exothermic and thus to generate heat in response to UV exposure, at least one aspect of the present invention is directed to the
35 inclusion of a TACl in a hydrogel precursor where a photo initiator is also present so as to allow the TACl to take advantage of the heat generated by the radical polymerization

reaction induced by a photo initiator. It is also contemplated that a TACI can be included where multiple photo initiators are present. The presence of multiple photo initiators provides for the potential benefits of multiple initiators discussed above yet also provides for the triggering of a TACI where the heat generated by one photo initiator may be
5 insufficient to trigger or fully trigger the TACI (depending on the photo initiators and the TACI involved), whereby the TACI can further promote or complete the polymerization of the functional monomer and other monomeric residues in a hydrogel precursor. Multiple TACIs are also contemplated.

Nowhere in the literature of prior art or clinical experience has there been any
10 report or knowledge of utilizing the combination of one or more photo initiators and a TACI in order to obtain the more complete polymerization of a hydrogel precursor, thereby leading to a more stable, less malodorous, and/or less skin irritating hydrogel.

As is also noted above, cross-linking agents are desirably used to cross-link the present hydrogels. Examples of multi-functional cross-linking agents which may be used
15 include, for example, methylene-bis-acrylamide and diethylene glycol diacrylate which are both commercially available from Polysciences, Inc., Warrington, Pa. Additional examples of cross-linking agents which may be acceptable for use in the present invention include: poly(ethylene glycol) diacrylate, triethylene glycol-bis-methacrylate, ethylene glycol-bis-methacrylate, ethylene glycol-dimethacrylate, bisacrylamide, triethyleneglycol-bis-acrylate,
20 3,3'-ethylidene-bis(N-vinyl-2-pyrrolidone), trimethylolpropane trimethacrylate, glycerol trimethacrylate, polyethylene glycol dimethacrylate, and other multifunctional polyacrylate and polymethacrylate crosslinkers.

The amount of cross-linking agent is desirably within the range of about 0.01 to about 2% by weight of the hydrogel precursor and, more desirably, within the range of
25 about 0.05 to about 0.5% by weight of the hydrogel precursor.

We will now turn to specific exemplary embodiments of hydrogels of the present invention. A number of exemplary formulas are provided below. With the exception of Formula 1 which is provided as a control, each of Formulas 2-6 relate to at least one aspect of the present invention. In each of the Formulas, the starting materials were
30 mixed in the order given below and placed under a Fusion Systems 600 Watt Continuous UV Lamp.

UV Curing equipment and process parameters: a F600S Ultra-violet Lamp System (Fusion UV Systems, Inc., Woburn, MA) was used at a dose of about 5.084 J/cm²

FORMULA 1 (Control)

35 48.64% DI Water

47.13% Monomer (N,N-Dimethylaminoethyl acrylate ammonium DMS (available from Ciba Specialty Chemicals under the tradename AGEFLEX[®] FA1Q80DMS))

0.1% Photo initiator (IRGACURE[®] 184)

0.09% Cross-linking Agent (Methylene-Bis-Acrylamide (available from Aldrich))

5 2.11% Electrolyte (Aluminum Potassium Sulfate)

1.5% Buffer (Sodium hydroxide)

0.43% DMSO

FORMULA 2

10 33% DI Water

63.8% Monomer (AGEFLEX[®] FA1Q80DMS)

0.1% Photo initiator (IRGACURE[®] 184)

0.1% Photo initiator (IRGACURE[®] 2959)

0.2% Cross-linking Agent (Poly(ethylene glycol)-400-diacrylate (PEG 400 DA))

15 1% Electrolyte (Potassium Sulfate)

0.8% Buffer (Sodium hydroxide)

1% Solubilizer (Hydroxypropyl β -cyclodextrin)

FORMULA 3

20 35.78% DI Water

60.91% Monomer (AGEFLEX[®] FA1Q80DMS)

0.1% Photo initiator (IRGACURE[®] 184)

0.1% Photo initiator (IRGACURE[®] 2959)

0.1% Chemical initiator (Sodium metabisulfite)

25 0.2% Cross-linking Agent (PEG 400 DA))

1% Solubilizer (Hydroxypropyl β -cyclodextrin)

1% Electrolyte (Potassium Sulfate)

0.8% Buffer (Sodium hydroxide)

0.01% Coloring additive (FD&C Green #3)

30

FORMULA 4

31.79% DI Water

65% Monomer (AGEFLEX[®] FA1Q80DMS)

0.1% Photo initiator (IRGACURE[®] 184)

35 0.1% Cross-linking Agent (Methylene-Bis-Acrylamide)

1% Electrolyte (Potassium Sulfate)

- 0.8% Buffer (Sodium hydroxide)
- 0.2% Aloe Vera gel
- 0.01% Coloring additive (FD&C Blue #1)
- 1% Solubilizer (Hydroxypropyl β -cyclodextrin)

5

FORMULA 5

- 34.6% DI Water
- 6.2% Monomer (AGEFLEX[®] FA1Q80DMS)
- 0.1% Photo initiator (IRGACURE[®] 184)
- 10 0.1% Photo initiator (IRGACURE[®] 2959)
- 0.2% Cross-linking Agent (PEG 400 DA)
- 1% Solubilizer (Hydroxypropyl β -cyclodextrin)
- 1% Electrolyte (Potassium Sulfate)
- 0.8% Buffer (Sodium hydroxide)
- 15 0.2% Aloe Vera gel

FORMULA 6

- 35.49% DI Water
- 6.1% Monomer (AGEFLEX[®] FA1Q80DMS)
- 20 0.1% Photo initiator (IRGACURE[®] 184)
- 0.1% Second initiator (IRGACURE[®] 2959)
- 0.1% Photo initiator (Sodium metabisulfite)
- 0.2% Cross-linking Agent (PEG 400 DS))
- 1% Solubilizer (Hydroxypropyl β -cyclodextrin)
- 25 1% Electrolyte (Potassium Sulfate)
- 0.8% Buffer (Sodium hydroxide)
- 0.2% Aloe Vera gel
- 0.01% Coloring additive (FD&C Green #3)

30 After being formed each of the hydrogels was tested for residual amounts of 1) quaternary acrylic monomer, 2) acrylic acid, and 3) methyl acrylate. The amounts of residual quaternary acrylic monomer, residual acrylic acid and residual methyl acrylate were each tested for by high pressure liquid chromatography (HPLC).

HPLC Method - AGEFLEX Quaternary Monomer

Approximately 1 gram of the hydrogel was placed into a microwave extraction liner. 10 ml of IPA was added. The liner was placed in a microwave extraction vessel and placed in the microwave oven. The extraction occurred under the following conditions:

5 Extraction Conditions:

System: CEM MARSX Microwave 1200 watt extraction system

Power: 100%

Solvent: IPA

Ramp: 1.0 min

10 Hold time: 5 min/sample

Temp: 80°C

Once extraction was complete HPLC analysis of AGEFLEX Quaternary Monomer was performed under the following conditions:

System: HP 110 Quaternary HPLC

15 Column: Supelcosol LC-SCX (4.6 x 250mm) Cat# 5-8997

Mobile Phase: 62% Acetonitrile/38% 0.14M Ammonium Formate

Flow rate: 1.0 ml/min

Detector: Agilent 1100 Series G1315A DAD at 210 nm, 20 Ref=350 nm, 90

Injection Vol: 2µl

20 Elution Time: 7.9 min

HPLC Method - Acrylic acid and Methyl acrylate

Approximately 0.1 gm of the monomer was accurately weighed into a 10.0 ml volumetric flask. Isopropyl alcohol (IPA) was added to the flask before placing in an ultrasonic bath for dissolution. Once dissolved the flask was dissolve to volume with IPA. 25 An aliquot of the solubilized monomer was filtered through a 0.45 µm PTFE membrane filter to make HPLC-ready.

Acrylic acid (Aldrich #14,723-0, 99%) stock standard was prepared in IPA at a concentration of 950 µg/ml. Four aliquots of 0.1, 0.5, 2.0 and 5.0 mls were taken from the stock standard and transferred to four 10.0 ml volumetric flasks to prepare working 30 standards with a concentration of 10 to 480 µg/ml.

Methyl acrylate (Aldrich M2,730-1, 99%) stock standard was prepared in IPA at a concentration of 730 µg/ml. Four aliquots of 0.5, 1.0, 3.0 and 6.0 mls were taken from the stock standard and transferred to four 10.0 ml volumetric flasks to prepare working 35 standards with a concentration of 36 to 440 µg/ml.

The HPLC analysis for Acrylic acid and Methyl acrylate was performed under the following conditions:

System: HP 110 Quaternary HPLC
 Column: Phenomenex Synergi 4 μ Polar-RP 80 \AA (4.6 x 75mm)
 5 Mobile Phase: 0.1% Formic acid/Ethanol/Methanol (96/3/1)
 Flow rate: 1.5 ml/min
 Detector: HP 1100 Diode Array at 210 nm,4 Ref=350 nm,90
 Injection Vol: 2 μ l
 Elution Time: Acrylic Acid -1.3 min
 10 Methyl Acrylate -3.6 min

The results of those tests are shown in TABLE 1 below.

TABLE 1

	% Residual Quaternary Monomer	% Residual Acrylic Acid	% Residual Methyl Acrylate
Formula 1	1.53	0.51	0.05
Formula 2	1.31	0.19	0.06
Formula 3	1.45	0.17	0.05
Formula 4	1.92	0.13	0.06
Formula 5	1.74	0.15	0.05
Formula 6	1.54	0.17	0.06

15 As can be seen from TABLE 1, the hydrogels formed from the precursor formulas set forth in Formulas 2-6 demonstrate an overall reduction in monomeric residues. Most notably there is a significant decrease in the percentage of residual acrylic acid in the hydrogel. In some instances there is also shown a reduction in the percentages of residual quaternary monomer and/or residual methyl acrylate. While the decrease in residual quaternary monomer and/or residual methyl acrylate is small or even non-existent in some instances, the overall decrease in monomeric residues is significant.

20 It will be appreciated that as acrylic acid is known to be a skin irritant as well as to put off an acrid odor, the resulting hydrogels of the present invention are significantly less malodorous and less irritating to the skin.

25 It is of note that the present invention further distinguishes itself from prior hydrogels which incorporated dimethyl sulfoxide (DMSO) as an organic solvent. While DMSO was believed to be an excellent vehicle to pass through the skin of a subject and

was thought to have been able to carry water to the skin of the subject in order to provide a good electrical conductivity path, it also may carry irritating residues into the inner skin layers thus potentially resulting in a rash or other undesired bodily reaction.

5 The hydrogels of the present invention are able to withstand the high voltages and currents of defibrillation and cardiac pacing. The hydrogels of the present invention are particularly suited for use in electronic medical devices such as: sensing electrodes which are used for recording or monitoring (e.g., for electrocardiogram, electroencephalogram, or electromyogram); stimulation electrodes which are used to stimulate a subject (e.g., for transcutaneous electrical nerve stimulation, for wound healing, for muscle stimulation
10 (e.g., for physical therapy), for external pacing, for defibrillation); electro-surgical and/or ablation grounding electrodes; and electro-transport electrodes (e.g., for the iontophoresis or electrophoresis of drugs into a subject).

One problem with past such devices is that the hydrogels used were not chemically compatible with aluminum or stainless steel (the hydrogel would cause
15 corrosion of such metal contacting it); or if the hydrogel did not corrode the metal, it did not pass standards testing for biocompatibility and electrical properties as developed by the Association for the Advancement of Medical Instrumentation (AAMI) and accepted by the American National Standards Institute. Therefore, prior acceptable hydrogel devices used tin electrodes or other metal electrodes. However, use of aluminum electrodes is desired
20 because such electrodes are radiolucent and, therefore, do not interfere with radio assays of a subject which includes such an electrode whereas electrodes made of tin or other metals do interfere with such assays. The hydrogels of the present invention present a family of hydrogels which do not include chlorides, and which are, therefore, chemically compatible with aluminum and/or stainless steel electrodes contacting the hydrogel.

25 In summary, it has been discovered that the hydrogel precursors of the present invention provide for a hydrogel which provide for a reduction in odor and skin irritation to the patient as compared to prior hydrogels. The novel formulations provide the ability of using the hydrogel or devices incorporating the hydrogel (e.g., electrodes) for longer periods of time without concern or with reduced concern for skin irritation and/or malodor.
30 The formulations of the present invention desirably provide or are directed to at least one of the following: a more efficient polymerization process, a synergistic initiation system (or at least one which has a synergistic effect) including UV-activated initiators (photoinitiator) and/or heat-activated initiators, a polymerizing monomer solution that includes solubilizing agents to improve the homogeneity of the polymerizing solution, complexing agents to
35 lower the volatility of volatile compounds, and skin care ingredients that could protect skin against undesirable elements.

It should be noted that whereas various mechanisms have been put forth here to explain the discovery of the reduction in skin irritation and/or malodorous properties in connection with enhanced or more complete polymerization of the monomer and/or monomeric residue in the hydrogels of the present invention, the precise reasoning and/or mechanism of this skin irritation and/or malodor relieving process has not been totally clarified. For example, the role of hydrolysis of the hydrogel and/or the production of byproducts may play some role. The presence of residue in the monomer as received from the manufacturer and the subsequent reactions involving such monomeric residue may be additional contributory factors of significance. Although the precise origins of the skin irritation and odor relief have not been totally elucidated, nonetheless, this does not diminish a spectacular discovery which is pertinent to this invention, namely that enhanced polymerization and/or complexation of volatile molecules of hydrogel monomers dramatically relieves the malodorous and skin-toxic properties in hydrogels.

It should also be noted that while the above specific examples show particular desired embodiments of the present invention, substitution of the specific constituents of those examples with materials as disclosed herein and as are known in the art may be made without departing from the scope of the present invention. Thus, while different aspects of the present invention have been shown and described, various modifications may be made without departing from the scope of the present invention, and all such modifications and equivalents are intended to be covered.

We claim:

1. A composition for an electrically conductive hydrogel comprising:
a monomer;
5 a first initiator; and
a cross-linking agent;
wherein the initiator is a thermally activated chemical initiator.
2. The composition of claim 1 wherein the monomer is selected from the group
10 consisting of N,N-Dimethylaminoethyl acrylate ammonium DMS, dimethyl amino ethyl
methacrylate, acrylamido methyl propane sulfonic acid and their salts.
3. The composition of claim 1 further comprising a skin health agent.
- 15 4. A composition for an electrically conductive hydrogel comprising:
a monomer, wherein the monomer is about 10% to about 80% by weight of the
composition;
a thermally activated chemical initiator;
a cross-linking agent; and
20 a solubilizer;
characterized in that the solubilizer allows for a higher initiator concentration to be
solubilized in the composition; and such that the composition has a higher polymerizing
potential than a similar composition without the solubilizer.
- 25 5. An electrode comprising an electrically conductive adhesive hydrogel formed from
a composition comprising:
a monomer;
a first initiator; and
a cross-linking agent;
30 wherein the first initiator is a thermally activated chemical initiator.
6. The composition or electrode of claims 1 or 5 wherein the thermally activated
chemical initiator is selected from the group consisting of disulfide based, peroxide based,
and persulfate based initiators.

35

7. The composition or electrode of claims 1 or 5 wherein the thermally activated chemical initiator is sodium metabisulfite.
8. The composition or electrode of claims 1, 4, or 5 further comprising one or more second initiators.
9. The composition of claim 8 wherein the one or more second initiators are chemical or photo initiators.
10. The composition of claims 4 or 8 wherein the one or more second initiators are capable of activating the thermally activated chemical initiator.
11. The composition or electrode of claims 1, 4, or 5 further comprising a conductivity enhancer.
12. The composition or electrode of claims 1, 4, or 5 further comprising a buffer.
13. The composition or electrode of claims 1 or 5 further comprising a solubilizer.
14. The composition or electrode of claims 1 or 5 wherein the monomer comprises about 10% to about 80% by weight of the composition.
15. The composition or electrode of claims 1 or 5 wherein the monomer comprises about 40% to about 75% by weight of the composition.
16. The composition or electrode of claims 1, 4, or 5 wherein the thermally activated chemical initiator comprises about 0.01% to about 5% by weight of the composition.
17. The composition or electrode of claim 8 wherein the one or more second initiators comprise about 0.01% to about 2% by weight of the composition.
18. The composition or electrode of claims 1, 4, or 5 wherein the cross-linking agent comprises about 0.01% to about 2% by weight of the composition.
19. The composition of claim 11 wherein the conductivity enhancer comprises less than about 5% by weight of the composition.

20. The composition of claims 4 or 13 wherein the solubilizer comprises less than about 20% by weight of the composition.
- 5 21. The composition of claims 4 or 13 wherein the solubilizer is selected from the group consisting of cyclodextrin, cyclodextrin derivatives, and hydrotropes.
22. The composition of claims 4 or 13 having a lower concentration of residual monomeric compounds present in the hydrogel than that of a similar hydrogel without the
10 solubilizer.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/029256

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/70 C08L39/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, PAJ, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	US 2004/057986 A1 (MERRIGAN STEVE RAY ET AL) 25 March 2004 (2004-03-25) the whole document	1-22
X	US 4 581 821 A (CAHALAN ET AL) 15 April 1986 (1986-04-15) column 1, line 64 - column 3, line 43; claims 1-16; examples 1-27	1-22
X	US 5 264 249 A (PERRAULT ET AL) 23 November 1993 (1993-11-23) column 1, line 60 - column 3, line 39; claims 1-22	1-22
X	US 4 391 278 A (CAHALAN ET AL) 5 July 1983 (1983-07-05) column 1, line 60 - column 3, line 41; claims 1-15; examples 1-27	1-22
	-/--	

Further documents are listed in the continuation of box C. Patent family members are listed in annex.

° Special categories of cited documents :

<p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p>	<p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>* & * document member of the same patent family</p>
--	--

Date of the actual completion of the international search <p style="text-align: center;">24 March 2005</p>	Date of mailing of the international search report <p style="text-align: center;">06/04/2005</p>
---	---

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer <p style="text-align: center;">Felder, C</p>
--	--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/029256

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 800 685 A (PERRAULT ET AL) 1 September 1998 (1998-09-01) cited in the application column 1, line 65 - column 3, line 13; claims 1-26; examples 1-7 -----	1-22

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US2004/029256

Patent document cited in search report	Publication date	Publication date	Patent family member(s)	Publication date
US 2004057986	A1	25-03-2004	EP 1245241 A1	02-10-2002
			BR 0208502 A	20-04-2004
			CA 2437757 A1	10-10-2002
			CN 1501817 A	02-06-2004
			JP 2004525226 T	19-08-2004
			WO 02078758 A1	10-10-2002
US 4581821	A	15-04-1986	US 4391278 A	05-07-1983
			CA 1153427 A1	06-09-1983
US 5264249	A	23-11-1993	NONE	
US 4391278	A	05-07-1983	CA 1153427 A1	06-09-1983
			US 4581821 A	15-04-1986
			CA 1237229 A2	24-05-1988
			DE 2966933 D1	24-05-1984
			EP 0012402 A1	25-06-1980
			ES 486582 A1	16-06-1980
			FR 2443843 A1	11-07-1980
			JP 1436057 C	25-04-1988
			JP 55081635 A	19-06-1980
			JP 62044933 B	24-09-1987
US 5800685	A	01-09-1998	AU 736284 B2	26-07-2001
			AU 5426598 A	22-05-1998
			BR 9712452 A	05-03-2002
			CA 2270074 A1	07-05-1998
			EP 0934593 A1	11-08-1999
			JP 2001504262 T	27-03-2001
			WO 9819311 A1	07-05-1998
			US 6039940 A	21-03-2000
			US 6800278 B1	05-10-2004